title: Retinal and renal vascular permeability changes caused by stem cell stimulation in alloxan-induced diabetic rats, measured by extravasation of fluorescein.
abstract: OBJECTIVE
  To determine whether treatment with the stem cell stimulator Olimpiq® Stem×Cell prevents increase of retinal and renal vascular permeability in alloxan-induced diabetic rats.
  
  
  METHODS
  Two groups of Wistar rats were made diabetic by single intraperitoneal injection of Alloxan. The third, the control group, received vehicle alone. One diabetic group received Olimpiq® Stem×Cell treatment for 4 weeks. The permeability of the blood-retinal barrier (BRB) and renal vessels were measured by the extravasation of fluorescein-labeled bovine serum albumin.
  
  
  RESULTS
  Six weeks subsequently to Alloxan injection, significantly elevated the tissue fluorescence, the renal vascular leakage and BRB breakdown was demonstrated in the diabetic group, compared to the nondiabetic group. Olimpiq® Stem×Cell treatment significantly reduced the BRB breakdown, tissue fluorescence, and vascular leakage.
  
  
  CONCLUSIONS
  Olimpiq® Stem×Cell would be a useful choice of treatment for complications associated with increased vascular permeability of diabetes, such as retinopathy or nephropathy.
authors.affiliation: Department of Pharmacology, University of Medicine and Pharmacy, Gheorghe Marinescu str. 38, 540139 Targu Mures, Romania. md.doczi@gmail.com
authors.forename: Z
authors.initials: Z
authors.lastname: Doczi-Keresztesi
authors.forename: J
authors.initials: J
authors.lastname: Jung
authors.forename: I
authors.initials: I
authors.lastname: Kiss
authors.forename: T
authors.initials: T
authors.lastname: Mezei
authors.forename: L
authors.initials: L
authors.lastname: Szabo
authors.forename: I
authors.initials: I
authors.lastname: Ember
mesh_terms: D000496:Alloxan; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects*; D045424:Complex Mixtures / Q000494:pharmacology* / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D005123:Eye / Q000098:blood supply; D019793:Fluorescein / Q000493:pharmacokinetics; D005456:Fluorescent Dyes / Q000493:pharmacokinetics; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007668:Kidney / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology; D008297:Male; D051381:Rats; D012160:Retina / Q000378:metabolism* / Q000473:pathology; D013234:Stem Cells / Q000187:drug effects*; D014018:Tissue Distribution / Q000187:drug effects
chemical_list: D045424:Complex Mixtures; D005456:Fluorescent Dyes; D007004:Hypoglycemic Agents; D000496:Alloxan; D019793:Fluorescein